Pacira BioSciences (PCRX) Competitors $23.69 +0.52 (+2.24%) Closing price 04:00 PM EasternExtended Trading$23.70 +0.01 (+0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Its Competitors Perrigo Supernus Pharmaceuticals Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Which has better earnings & valuation, PRGO or PCRX? Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.86-$171.80M-$1.31-20.82Pacira BioSciences$700.97M1.56-$99.56M-$2.28-10.39 Is PRGO or PCRX more profitable? Perrigo has a net margin of -4.16% compared to Pacira BioSciences' net margin of -14.78%. Pacira BioSciences' return on equity of 13.78% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-4.16% 8.93% 3.87% Pacira BioSciences -14.78%13.78%7.00% Do insiders & institutionals have more ownership in PRGO or PCRX? 95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.7% of Perrigo shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, PRGO or PCRX? Perrigo has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Does the media favor PRGO or PCRX? In the previous week, Perrigo had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Perrigo and 3 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 0.98 beat Pacira BioSciences' score of 0.25 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer PRGO or PCRX? Perrigo currently has a consensus price target of $33.00, suggesting a potential upside of 20.97%. Pacira BioSciences has a consensus price target of $26.44, suggesting a potential upside of 11.63%. Given Perrigo's higher probable upside, equities analysts plainly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryPacira BioSciences beats Perrigo on 10 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-10.3920.9727.1520.13Price / Sales1.56292.39441.18127.16Price / Cash5.3742.7337.5058.41Price / Book1.417.748.085.60Net Income-$99.56M-$54.96M$3.16B$248.43M7 Day Performance2.09%6.04%3.77%5.15%1 Month Performance-4.74%4.47%3.90%7.62%1 Year Performance16.47%6.12%34.22%21.56% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.3681 of 5 stars$23.69+2.2%$26.44+11.6%+10.5%$1.07B$700.97M-10.39720News CoveragePRGOPerrigo4.8488 of 5 stars$26.73+0.7%$33.00+23.5%+2.7%$3.65B$4.37B-20.408,379SUPNSupernus Pharmaceuticals1.8604 of 5 stars$31.52+1.2%$36.00+14.2%+22.4%$1.74B$661.82M28.40580NKTRNektar Therapeutics4.8645 of 5 stars$25.84+0.3%$84.17+225.7%+26.6%$319.60M$98.43M-2.69220Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeOMEROmeros3.2861 of 5 stars$3.00-6.3%$18.00+500.0%-13.3%$187.50MN/A-1.13210ASMBAssembly Biosciences3.786 of 5 stars$18.12+4.7%$33.00+82.1%+35.9%$132.21M$28.52M-2.91100Trending NewsHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5998 of 5 stars$3.35+28.8%N/A+107.4%$38.90M$37.87M-13.4080Trending NewsLLYEli Lilly and Company4.9842 of 5 stars$779.35+0.5%$1,011.61+29.8%-15.7%$734.92B$45.04B63.4147,000Trending NewsAnalyst ForecastOptions VolumeAnalyst RevisionJNJJohnson & Johnson4.8738 of 5 stars$152.58+0.1%$170.88+12.0%+6.1%$366.71B$88.82B16.97138,100Trending NewsUpcoming EarningsAnalyst ForecastABBVAbbVie4.7878 of 5 stars$185.80+1.9%$211.29+13.7%+13.5%$322.03B$56.33B79.0655,000Trending NewsAnalyst RevisionMRKMerck & Co., Inc.4.9977 of 5 stars$79.19+0.1%$109.19+37.9%-33.6%$198.62B$64.17B11.5375,000Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
